Asia’s Largest Web3 Event TOKEN2049 Singapore Announces Title Sponsors
7.6.2022 09:37:00 EEST | Business Wire | Press release
TOKEN2049, Asia’s premier crypto conference, has announced a number of high profile Title Sponsors for its much-anticipated Singapore debut. Taking place from 28-29 September 2022, this year’s event marks TOKEN2049’s first physical presence in Singapore, which will be held in conjunction with the Formula 1 Singapore Grand Prix 2022, ahead of the race weekend.
As the flagship event of Asia Crypto Week, the conference is set to see over 3,000 attendees as they gather to learn from prominent thought leaders and innovators across the crypto industry, including the CEOs and founders of some of the world’s largest crypto-related projects. Over 130 sponsors and exhibitors have already confirmed their participation with numbers steadily rising as anticipation builds ahead of September.
“TOKEN2049 is shaping up well in bringing together the brightest minds of our ecosystem in exploring pathways of innovation and collaboration. As one of the leading enablers dedicated to unlocking the full potential of digital assets, we look forward to the dialogue and conversations at this gathering,” said Cynthia Wu, Founding Partner at Matrixport.
With this year’s agenda spanning institutional investment trends to the rise of the metaverse and Web3, the diversity of this year’s title sponsors for TOKEN2049 Singapore is a testament to a flourishing industry ecosystem. This includes Singapore-based crypto unicorn and digital assets financial services platform Matrixport; leading cryptocurrency exchange app and Formula 1 global partner Crypto.com; global leader in digital assets products and infrastructure Amber Group; revolutionary social currency $WHALE which is backed by one of the largest and most valuable NFT collections in the world; community-governed DeFi platform MantraDAO; and collaborative Web3 credential infrastructure Project Galaxy.
Celebrating the upcoming event, Raphael Strauch, Founder of TOKEN2049 said: “Within the past few months, the crypto ecosystem has seen a whirlwind of change and growth, and it’s only befitting that we’re gathering in Singapore — one of the region’s leading innovation hubs — to celebrate how far we’ve come.”
Alongside its impressive speaker line-up including Pantera Capital CEO Dan Morehead, Ava Labs CEO Emin Gün Sirer, Three Arrows Capital CIO and CEO Su Zhu. Additional title sponsors at the event include enterprise-grade crypto infrastructure company Fireblocks; cryptocurrency exchange and derivative trading platform Bitmex; the EOS Network Foundation which is building a coordinated future for the EOS Network through decentralization and community; decentralised and open-source platform Syscoin; Asia’s leading institutional digital asset custodian Hextrust; global online identity verification platform Trulioo; the blockchain platform TRON and the first official Ethereum Virtual Machine based on the EOS network Trust EVM.
“From our decorated bench of Title Sponsors to our speaker line-up, we’re thrilled to see continued support from so many of the industry’s leading organizations and are looking forward to spotlighting some of the most exciting, emerging voices across the ecosystem. We’ve seen tremendous interest from potential speakers and sponsors alike, and are thrilled to deliver a top-notch conference experience for all. To that end, we are very excited to be hosting a large closing party CÉ LA VI Singapore, on the rooftop deck of the Marina Bay Sands, overlooking the F1 Grand Prix track, with several notable European DJs flying in to grace the event,” continued Strauch.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/
Raphael Strauch, Founder of TOKEN2049 is available for interview.
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606006051/en/
Contact information
Media:
Melissa Esguerra
Senior Consultant
Wachsman
melissa.esguerra@wachsman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom